{"name":"dr hab. n. med. Agnieszka Wierzbowska","slug":"dr-hab-n-med-agnieszka-wierzbowska","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"DAC","genericName":"DAC","slug":"dac","indication":"Acute myeloid leukemia (in combination with cytarabine)","status":"marketed"},{"name":"Consolidation, I HAM cycle","genericName":"Consolidation, I HAM cycle","slug":"consolidation-i-ham-cycle","indication":"Acute myeloid leukemia (AML) consolidation therapy","status":"phase_3"},{"name":"Consolidation, III HiDAraC cycle","genericName":"Consolidation, III HiDAraC cycle","slug":"consolidation-iii-hidarac-cycle","indication":"Acute myeloid leukemia (AML) consolidation therapy","status":"phase_3"},{"name":"II Consolidation HiDAraC","genericName":"II Consolidation HiDAraC","slug":"ii-consolidation-hidarac","indication":"Acute myeloid leukemia (AML) consolidation therapy in first remission","status":"phase_3"}]}],"pipeline":[{"name":"DAC","genericName":"DAC","slug":"dac","phase":"marketed","mechanism":"DAC is a cytidine deaminase inhibitor that enhances the activity of cytarabine by preventing its inactivation.","indications":["Acute myeloid leukemia (in combination with cytarabine)","Acute lymphoblastic leukemia"],"catalyst":""},{"name":"Consolidation, I HAM cycle","genericName":"Consolidation, I HAM cycle","slug":"consolidation-i-ham-cycle","phase":"phase_3","mechanism":"The I-HAM consolidation cycle combines idarubicin, high-dose cytarabine, and mitoxantrone to induce cytotoxic effects in acute myeloid leukemia cells.","indications":["Acute myeloid leukemia (AML) consolidation therapy"],"catalyst":""},{"name":"Consolidation, III HiDAraC cycle","genericName":"Consolidation, III HiDAraC cycle","slug":"consolidation-iii-hidarac-cycle","phase":"phase_3","mechanism":"HiDAraC (high-dose cytarabine consolidation) is a chemotherapy regimen that delivers high doses of cytarabine to inhibit DNA synthesis and induce apoptosis in leukemic cells.","indications":["Acute myeloid leukemia (AML) consolidation therapy"],"catalyst":""},{"name":"II Consolidation HiDAraC","genericName":"II Consolidation HiDAraC","slug":"ii-consolidation-hidarac","phase":"phase_3","mechanism":"II Consolidation HiDAraC is a high-dose cytarabine (ara-C)-based chemotherapy regimen used as consolidation therapy in acute myeloid leukemia.","indications":["Acute myeloid leukemia (AML) consolidation therapy in first remission"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"marketed":1,"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}